The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Open accessAbstract
BACKGROUND: Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). OBJECTIVE: We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment. METHODS: A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients achieving Eczema Area and Severity Index (EASI)-50 at week 12. RESULTS: In total, 209 patients received the study drug. At week 12, significantly more patients achieved EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%); patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50 compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and mostly mild or moderate. LIMITATIONS: Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety evaluations. CONCLUSION: When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“Treatment of AD with systemic agents such as cyclosporine can decrease skin IL-13 levels,(12) and recent trials have reported improved clinical responses in patients with moderate-to-severe AD treated with dupilumab, a monoclonal antibody against IL-4Ra, which inhibits IL-13/ IL-4 signaling.(13,14) Together, these dat…”
BackgroundSelf-citationLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationGuidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Self-citationLoricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Kim, B. E., Leung, D. Y. M., Boguniewicz, M., & Howell, M. D. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.006 · Cited by 538
Hanania, N. A., Korenblat, P., Chapman, K. R., Bateman, E. D., Kopecky, P., Paggiaro, P., Yokoyama, A., Olsson, J., Gray, S., Holweg, C. T. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30265-x · Cited by 469
Self-citationAtopic dermatitis: A practice parameter update 2012
Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417
Guidelines of care for atopic dermatitis
Hanifin, J. M., Cooper, K. D., Ho, V. C., Kang, S., Krafchik, B. R., Margolis, D. J., Schachner, L. A., Sidbury, R., Whitmore, S. E., Sieck, C. K., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.08.003 · Cited by 387
Cited by
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationGuttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Self-citationTreatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Self-citationBiomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Self-citationGuttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Self-citationTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345
Self-citationUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection
Fishbein, A. B., Silverberg, J. I., Wilson, E. J., & Ong, P. Y. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.06.044 · Cited by 321
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Renert-Yuval, Y., Del Duca, E., Pavel, A. B., Fang, M., Lefferdink, R., Wu, J., Diaz, A., Estrada, Y. D., Canter, T., Zhang, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.001 · Cited by 168
Pruritus in allergy and immunology
Yang, T.-L. B., & Kim, B. S. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.016 · Cited by 112
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Efficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Bernardo, D., Bieber, T., & Torres, T. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00793-5 · Cited by 43
Self-citationKołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity and did not require treatment discontinuation [129,131,132].”
Metadata
- Authors
- Simpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., Lin, C.-Y., Voulgari, A., Yen, K., & Omachi, T. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 78
- Issue
- 5
- Pages
- 863-871.e11
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2783829013
- Cited by
- 331
- References
- 29
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.